Non-Oncology Precision Medicine Market Size, Share, and Trends

Non-Oncology Precision Medicine Market (By Product: Diagnostics, Therapeutics; By Application: Oncology, CNS, Immunology, Respiratory, Infectious Diseases, Neurology, Others; By End-use: Hospitals, Diagnostic Centers, Research & Academic Institutes, Others; By Ecosystem: Applied Sciences, Precision Diagnostics, Precision Therapeutics, Digital Health and Information Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

  • Last Updated : September 2023
  • Report Code : 1798
  • Category : Healthcare

Non-Oncology Precision Medicine Market Size and Companies

The global non-oncology precision medicine market size was valued at US$ 69.66 billion in 2022 and it is expected to surpass around US$ 176.61 billion by 2032 with a registered CAGR of 9.80% over the forecast period 2023 to 2032.

Non-Oncology Precision Medicine Market Size 2022 to 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Growth Factors

Headways in disease biologics will drive the development of non-oncology precision medicine. Improvement of fresher therapeutics approaches including quality treatment for disease treatment and expanding number of patients going through prescient analysis will push the market development. Then again, significant expense and expected danger to individual wellbeing information are a portion of the variables that might defeat the market development. 

There have been critical improvements in the market somewhat recently. The quantity of organizations, government, and private examination establishments associated with the business has been consistently developing. Constant and untiring endeavors of researchers in surveying the human genome and distinguishing genomic biomarkers have been productive. Additionally, government drives play likewise had a significant impact being the development of the market.

Right now, the market is overwhelmed by non-oncology drugs. In any case, expanded R&D exercises for different illnesses are projected to build the number of medications for cardiovascular, irresistible, and neurological sicknesses among others. The quantity of non-oncology accuracy medication drugs is anticipated to develop dramatically, and the consistent extension of the non-oncology accuracy medication portfolio will drive the business development.

Report Scope of the Non-Oncology Precision Medicine Market

Report Coverage Details
Market Size by 2032 USD 176.61 Billion
Growth Rate from 2023 to 2032

CAGR of 9.80%

Largest Market North America
Fastest Growing Region Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product, Application, End-use, Ecosystem, Geography
Companies Mentioned Pfizer Inc., Qiagen Inc., Quest Diagnostics Inc., Medtronic, Novartis, Laboratory Corporation of America Holdings, bioMérieux SA, Abbott Laboratories, F. Hoffmann-La Roche A, Eli Lilly & Company


A Glance at Chronic Diseases

The most common chronic disorders include high cholesterol, depression, hypertension, chronic obstructive pulmonary disease, diabetes, epilepsy, chronic kidney disorder, ischemic/coronary heart disease, heart failure, arthritis, and Alzheimer’s disease and dementia. These common disorders affect millions of individuals globally. As per the reports of World Health Organization (WHO), approximately 50 million or more are suffering from dementia, and the same number of individuals are fighting epilepsy. From these cases of dementia, about 60 % to 70% are the case of Alzheimer’s. Prominent players like Novartis AG and Pfizer are advancing therapies for the procedures of numerous nervous system diseases. The increasing concentration on a few therapies and the advancement of precision medicines for the populace impacted with chronic diseases is anticipated to bolster the extension of this sector. 

Evolution of Precision Medicines

The global precision medicine industry has shown a notorious advancements in the last decade. All the organizations, academic and research institutes, and governments included in this sector have shown a steady growth. Various scientists constantly working on the development of these medicines got fruitful results in the studies of human genome and establishing genomic biomarkers. Several governments have also showed their presence in these developments in the form of launching various initiatives.  For example, Barack Obama, the president of the U.S. announced the launch of an initiative named “Precision Medicine Initiative” in the year 2015. The purpose of this initiative was to create national research compliance of over 1 million Americans who contribute their inherited information as a means of their support to establish novel ways of enhancing the identification of the disorder and its treatment. These efforts resulted in the more number of drugs getting approval for the precision medicines. 

The precision medicines accessible based on the numbers in the market was only 5 in the year 2005. This single digit grew to 81 in the year 2012. In 2016, the number of precision medicines available in the market were 132. As per the data collected for 2020, around 286 drugs are readily available in the market and there are many such drugs are in datebook. Cancer drugs are influencing the market at present. However, research and development (R&D) activities for the disorders like infectious, cardiovascular, neurovascular, and others are burgeoning, which in turn is expected to propel the number of drugs present in the market. The portfolio of these medicines is constantly expanding which is going to augment the growth of this industry.

Product Insights

The rising number of non-oncology precision medicine treatments will support the market movement

The therapeutics section in the non-oncology precision medicine market is scheduled to observe a 11% development rate through 2032. There has been consistent development in non-oncology precision therapeutics for the designated therapy of conditions like a malignant growth, and hereditary infections. Besides, organizations are additionally engaged with the advancement of designated treatments for different signs including cardiovascular sicknesses, irresistible infections, and gastroenterology among others. The advancement of novel medications and expanding utilization of medications in non-oncology precision medicine treatment plans will fuel the development of the therapeutics portion.

Application insights

The rising pervasiveness of CNS issues overall will push the market interest. The CNS fragment caught over 15% of the portion of the overall industry in 2022. CNS problems such as Alzheimer's sickness, different sclerosis, epilepsy, and others influence a huge number of individuals across the world. As per the report of WHO, almost 50 million individuals overall have epilepsy. Above 50 million individuals experience the ill effects of dementia. Alzheimer's contributes to around 60-70% of these cases as it is the most considered normal type of dementia. Many organizations, for example, Pfizer and Novartis AG are associated with the advancement of designated treatments for the treatment of different sensory system problems. The developing spotlight on designated treatments and improvement of customized clinical treatment plans for individuals impacted with CNS problems will encourage the business extension.

End-use insights

Expanding mindfulness in regards to the significance of prescient diagnostics testing will drive the market income. The diagnostics centers portion is ready to extend at 14% CAGR through 2032 driven by the rising number of demonstratives focuses across the world. Headway in symptomatic methods and cutting-edge framework offering most ideal types of assistance to patient populace are a portion of the elements influencing the business movement. Furthermore, there has been development in mindfulness among the populace in regards to the significance of diagnostics. developingan interest in prescient indicative testing for disease, hereditary problems, and pneumonic issues among others will set out development open doors on the lookout.

Region Insights

Developing reception of non-oncology precision medicine approaches in the North American district will upgrade the market esteem. North American non-oncology precision medicine market represented 44% of income share in 2022 attributable to the rising commonness of malignant growth and hereditary problems, developing utilization of non-oncology precision medicine approaches, and the presence of noticeable organizations like Pfizer, Qiagen, Quest Diagnostics, and Roche. The locale is supposed to proceed with its strength during the conjecture time frame. This development can be ascribed to the high reception pace of medical care IT frameworks in clinical work processes and cutting-edge sequencing advancements, which help create customized and pharmacogenomic information effectively and proficiently.

In the Asia Pacific, the market is supposed to develop quickly over the estimated period. This is essentially attributable to the minimal expense related to leading clinical preliminaries of recently evolved non-oncology precision medicines and diagnostics around here, which draws in unfamiliar interests here.

Non-Oncology Precision Medicine Market Share, By Region, 2022 (%)

Likewise, great government drives to embrace customized medical services arrangements are further adding to showcase development in the district. For example, in Singapore, the National Precision Medicine program and the Three Beyonds program were sent off for advancing the take-up of innovations and computerized foundation for supporting customized medical services. The use of customized arrangements has the degree of creating explicit treatment answers for various patients because of the particular immuno-aggregate of the patient. Henceforth, approaches hold a promising answer for distinguishing hereditary, organic, and natural factors that could influence the antibody reaction and propose the elective measurement expected by a specific populace bunch.

Opportunities amid the Pandemic

The novel corona virus has had a significant impact on all the industries related to economy, growth, and physical and mental wellbeing of every populace. The purpose of every sector was to provide the best services with reference to safety and quality during this challenging period. The impact of the novel corona virus was the highest in the healthcare industry. However, this virus did not impact much on precision medicines. The outspread of the novel corona virus uplifted the demand for the technological developments, flexibility, and evolution of the non-oncology precision medicines. Rise in respiratory disorders at a quick rate is the propelling reason for the growth of the non-oncology precision medicines, as the same disorders need authentic drug procedure. A limelight has been brought by the novel corona virus in the markets of the non-oncology medicines. The novel corona virus did not have a straight effect on this market, but in return has offered lucrative opportunities for the advancement of these non-oncology precision medicines for numerous disorders like cardiovascular, among others.

Key Market Developments

  • The U.S. based company, Weill Cornell Medicine launched a campaign named “We’re Changing Medicine” by investing $1.5 billion in the year 2021. The aim of this campaign is to develop biomedical inventions in the areas of precision medicines, artificial intelligence and machine learning (AI & ML) as well as genomics.
  • An Indian multinational company Infosys launched a precision medicine solution on the basis of SAP technology for pharmaceutical organizations in the year 2020. This solution employs analytics, blockchain, as well as IoT to aim at patient management, supply chain and regulatory agreements.
  • In July 2019, Pfizer reported the cooperation with Synapse to propel malignant growth research. This joint effort was meant to zero in on sub-atomic testing and treatment decisions on non-oncology precision oncology accordingly growing the item portfolio.
  • In February 2019, Labcorp reported the development of a helpful medication checking portfolio DoseASSURE, to treat specific provocative illnesses including Crohn's infection and rheumatoid joint pain, accordingly fortifying its administrative role in non-oncology precision medicine.

Competitive Landscape 

The global non-oncology precision medicine market appears to be extremely competitive in account of the various prominent players present in the market. Prominent players in this market are constantly focusing on increasing their product portfolio by expanding their applications or by filing the new ones for the molecules. A few other strategic moves like academic collaboration, acquisitions and mergers to get in popularized molecule or arranging methods is also expected to witness a significant impact on the current trends of the market. Key market players also focusing on the advancement of the available products to expand their footprints and progress their positions in the market across the globe. In addition, several products are getting approved, and in the race to increase the number of precision drugs, constant advancing activities and other strategic moves by the market key players is playing a vital role in the expansion of this industry in the years to come.The key market players are continually participated in different formative procedures like association, joint efforts, new item dispatches, and acquisitions to reinforce their market position and gain a piece of the pie.

Some of the major market players in the global non-oncology precision medicine market include:

  • Pfizer Inc.
  • Qiagen Inc. 
  • Quest Diagnostics Inc.
  • Medtronic
  • Novartis
  • Laboratory Corporation of America Holdings 
  • bioMérieux SA
  • Abbott Laboratories
  • F. Hoffmann-La Roche A 
  • Eli Lilly & Company

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Product Type

  • Diagnostics
    • Genetic Tests
    • Biomarker Based Tests
    • Others
  • Therapeutics

By Application

  • Oncology
  • CNS
  • Immunology
  • Respiratory
  • Infectious Diseases
    • Respiratory Infections
    • Gastrointestinal Infections
    • Sexually Transmitted Infections
    • Others
  • Neurology
    • Neurodegenerative Disorders
    • Neuropsychiatric Disorders
    • Others
  • Cardiovascular
    • Cardiac Myopathies and Arrhythmia
    • Others
  • Lifestyle and Endocrinology
  • Gastroenterology
  • Others

By End-use

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Others

By Ecosystem

  • Applied Sciences
    • Genomics
    • By Technology
      • Polymerase Chain Reaction (PCR)
      • Precision Medicine Next-Generation Sequencing (PM NGS)
      • Genome Editing
      • Other Technologies
    • Pharmacogenomics
    • Other Applied Sciences
  • Precision Diagnostics
    • Molecular Diagnostics (MDx)
    • Medical Imaging
  • Digital Health and Information Technology
    • Clinical Decision Support Systems (CDSS)
    • Big Data Analytics
    • IT Infrastructure
    • Genomics Informatics
    • In-Silico Informatics
    • Mobile Health
  • Precision Therapeutics
    • Clinical Trials
    • Cell Therapy
    • Drug Discovery and Research
    • Gene Therapy

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

The global non-oncology precision medicine market size was reached at US$ 69.66 billion in 2022 and it is anticipated to rake around US$ 176.61 billion by 2032.

The global non-oncology precision medicine market is anticipated to grow at a CAGR of 9.80% over the forecast period 2023 to 2032.

The major players operating in the non-oncology precision medicine market are Pfizer Inc., Qiagen Inc., Quest Diagnostics Inc., Medtronic, Novartis, Laboratory Corporation of America Holdings, bioMérieux SA, Abbott Laboratories, F. Hoffmann-La Roche A, and Eli Lilly & Company.

North America region will lead the global non-oncology precision medicine market in the next ten years.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client